Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative ECX vs XP in Advanced Gastric Cancer
NCT01558947Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2011
- Primary completion
- Dec 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epirubicin in gastric cancer (GC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Relapse-Free Survival at 3 years and Safety and Security. Status: unknown.
02
Drugs
epirubicin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01558947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01558947.